Company Description
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC).
In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
| Country | France |
| Founded | 1999 |
| IPO Date | Feb 7, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 229 |
| CEO | Andre Choulika |
Contact Details
Address: 8, rue de la Croix Jarry Paris, 75013 France | |
| Phone | 33 1 81 69 16 00 |
| Website | cellectis.com |
Stock Details
| Ticker Symbol | CLLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001627281 |
| CUSIP Number | 15117K103 |
| ISIN Number | US15117K1034 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David J. Sourdive Ph.D. | Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC and Manufacturing and Director |
| Dr. Andre Choulika Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Arthur Stril | Chief Financial Officer and Chief Business Officer |
| Valerie Cros | Principal Financial Officer and Principal Accounting Officer |
| Jean Charles Epinat Ph.D. | Chief Technological Officer |
| Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer |
| Marie-Bleuenn Terrier | General Counsel and Secretary of the Board of Directors |
| Pascalyne Wilson | Director of Communications |
| Kyung Nam-Wortman | Executive Vice President and Chief Human Resources Officer |
| Stephan Reynier M.Sc. | Chief Regulatory and Pharmaceutical Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | 6-K | Report of foreign issuer |
| Apr 13, 2026 | 6-K | Report of foreign issuer |
| Mar 20, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 20, 2026 | 6-K | Report of foreign issuer |
| Mar 12, 2026 | 6-K | Report of foreign issuer |
| Jan 8, 2026 | 6-K | Report of foreign issuer |
| Dec 15, 2025 | 6-K | Report of foreign issuer |
| Dec 12, 2025 | SCHEDULE 13D/A | Filing |
| Dec 8, 2025 | 6-K | Report of foreign issuer |
| Dec 5, 2025 | 6-K | Report of foreign issuer |